Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › XNCR

Xencor

XNCR Rare disease Lead: Approved 3 Biotech Distilled articles ↓
HematologyImmunologyInfectious DiseaseNeurologyOncologyRenal Protein

Most recent annual filing: 2026-02-25

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. XmAb819 Ph3 readout2H 2026XmAb819 Ph3 readout, 2H 2026, notable
  2. XmAb541 readout2H 2026XmAb541 readout, 2H 2026, notable
  3. Plamotamab Ph1 readout2H 2026Plamotamab Ph1 readout, 2H 2026, notable
  4. XmAb942 UC interim~YE 2026XmAb942 UC interim, ~YE 2026, material
  5. XmAb412 Ph1 interim1H 2027XmAb412 Ph1 interim, 1H 2027, notable
  6. XmAb819 pivotal start2027XmAb819 pivotal start, 2027, routine
  7. XmAb942 UC topline2H 2027XmAb942 UC topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (36 active programs)

Technology platforms

XmAb Bispecific Fc Domain

Modular Fc engineering platform enabling multispecific antibody formats including 2+1 bispecific, CD3 T-cell engagers, CD28 co-stimulatory bispecifics, and trispecific formats. Applicable across oncology and autoimmune diseases.

Xtend Fc Domain

Engineered Fc domain designed to extend antibody half-life through FcRn receptor engagement on endothelial cells. Used in XmAb942, Ultomiris, tobevibart, and zaltenibart programs across IBD, PNH, and infectious disease.

Targets: FcRn

XmAb 2+1

Multivalent bispecific antibody format with two tumor-antigen binding domains and one T-cell binding domain, designed to enable more avid and selective tumor cell killing; used across oncology T-cell engager programs

XenLock

Bispecific antibody engineering platform used to develop novel bispecific antibodies; first candidate XmAb412 targets TL1A and IL-23 pathways for autoimmune and inflammatory disease

Targets: TL1A, IL-23p19

Discontinued (1)

Biotech Distilled coverage (3)

Articles open on Substack. Some deep dives are subscriber-only.